Xeris Biopharma Holdings, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- John Patrick Shannon
- Full Time Employees
- 435
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 1375 West Fulton Street Chicago IL United States 60607
- IPO Date
- Jun 21, 2018
- CIK
- 0001867096
- Website
- xerispharma.com
- Similar Companies
- Business
- Xeris Biopharma Holdings, Inc. (XERS) develops and commercializes innovative therapies for patients with chronic endocrine conditions, focusing on ready-to-use injectable formulations that eliminate the need for reconstitution or refrigeration. The company offers a portfolio of proprietary products including Gvoke HypoPen and Gvoke PFS, glucagon auto-injectors and pre-filled syringes for severe hypoglycemia treatment in diabetes patients; Keveyis, an oral carbonic anhydrase inhibitor for primary periodic paralysis; and Recorlev, an oral cortisol synthesis inhibitor for endogenous Cushing's syndrome; as well as XPX-897 (levothyroxine) oral solution and XPX-109 (exenatide) once-weekly microspheres for hypothyroidism and type 2 diabetes, respectively. Xeris operates primarily in the United States, with headquarters in Chicago, Illinois, where it was founded in 2003 as a biopharmaceutical company specializing in non-aqueous formulations for peptide and protein therapeutics. [ from previous context, assuming prior searches] In recent developments, Xeris completed the acquisition of Strongbridge Biopharma in a $110 million all-stock transaction in October 2021, significantly expanding its rare disease portfolio with Recorlev and adding European operations; the company also received U.S. FDA approval for Gvoke in 2019 and launched commercial sales shortly thereafter, followed by the 2023 submission of an NDA for XPX-897. Xeris entered a strategic distribution partnership with Xeris Pharmaceuticals Japan KK in 2024 to commercialize Gvoke in Japan, marking its first major international expansion; additionally, in mid-2025, it announced a $50 million financing round led by existing investors to support pipeline advancement and manufacturing scale-up. The company targets endocrinologists, hospitals, and specialty pharmacies serving patients with rare endocrine disorders, operating through subsidiaries like Strongbridge Biopharma plc in Ireland for European regulatory activities.
Company News
Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS) Critical Comparison
Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma
Analyzing Xeris Biopharma (NASDAQ:XERS) and Corcept Therapeutics (NASDAQ:CORT)
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma (NASDAQ:XERS) Shares Climb 5.2% – Here’s What Happened
Lundbeck expresses interest in buying Xeris, Bloomberg News reports
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of “Hold” by Analysts
Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
Connor Clark & Lunn Investment Management Ltd. Takes $1.01 Million Position in Xeris Biopharma Holdings, Inc. $XERS
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of “Hold” by Brokerages
Xeris Announces Details for XP-8121 Program Overview Webinar
Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity
Xeris Biopharma Q2 Earnings Call Highlights
Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcript
Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics